PEN
Penumbra, Inc.
Set alert
- YTD
- +2.59%
- 1 year
- +37.75%
- Open
- 320.56
- Prev close
- 321.97
- Mkt cap
- 12.56B
- Vol
- 497.75K
- Avg vol
- 342.85K
- EPS
- 4.07
- P/E
- 78.37
- Div yield
- 0.00%
More statistics
- Low
- 318.33
- High
- 321.83
- Forward P/E
- 52.34
- Beta
- 0.70
- Short ratio
- 5.55
- Inst. own
- 88.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 24, 2027
- 50-d avg
- 320.60
- 200-d avg
- 327.46
- 1y target
- 362.54
Key statistics
- Market cap
- 12.57B
- Enterprise value
- 12.24B
- Trailing P/E
- 78.42
- Forward P/E
- 52.34
- PEG ratio
- 3.63
- Price / sales
- 8.35
- Price / book
- 8.77
- EPS (TTM)
- 4.07
- Beta
- 0.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 10.67%
- Revenue (TTM)
- 1.50B
- Revenue growth
- 14.90%
- Free cash flow
- 161.10M
- Total cash
- 658.80M
- Total debt
- 212.71M
- Return on equity
- 11.37%
- Shares outstanding
- 39.39M
- Short % of float
- 6.60%
- 50-day average
- 320.60
- 200-day average
- 327.46
Analyst view
Consensus: hold
- Target (low)
- 320.00
- Target (mean)
- 362.54
- Target (high)
- 374.00
- Strong buy1
- Buy2
- Hold14
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 1.48.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 1.44 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 1.20 | 1.07 | -0.13 | -10.83% |
| Jul 30, 2026 | Jun 30, 2026 | 1.16 | 0.88 | -0.28 | -24.14% |
| May 6, 2026 | Mar 31, 2026 | 1.04 | 0.82 | -0.22 | -21.15% |
| Feb 25, 2026 | Dec 31, 2025 | 1.11 | 1.18 | +0.07 | +6.31% |
| Nov 5, 2025 | Sep 30, 2025 | 0.929 | 0.97 | +0.04 | +4.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 6, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Jun 11, 2026 | RBC Capital | reit | Sector Perform | Sector Perform |
| May 7, 2026 | Citigroup | main | Neutral | Neutral |
| May 7, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Feb 26, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Jan 20, 2026 | RBC Capital | down | Outperform | Sector Perform |
About Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- penumbrainc.com
News
- Penumbra Q3 EPS $1.07 Misses $1.25 Estimate, Sales $410.145M Beat $403.345M Estimate
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Penumbra Wins FDA Clearance For Lightning CAVT Technology To Treat Deep Vein Thrombosis, Backed By BOLT-DVT Trial Results
- Penumbra Presents Results From Subset Analysis Of STORM-PE Randomized Controlled Trial At Vascular InterVentional Advances Meeting
- Incuvate Files Patent Infringement Lawsuit Against Penumbra
- Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate
- Penumbra Initiates FORWARD Trial To Collect Safety, Efficacy Data On Mechanical Thrombectomy
- 8 Stocks to Buy as Merger-Mania Takes Over
- Honeywell To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday
- This JM Smucker Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Your note
Sign in to keep a note on PEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOSE ARANI | Director | Stock Award(Grant) | Feb 12, 2026 | 259,609 |
| ELSESSER ADAM | Chief Executive Officer | Stock Gift | May 18, 2026 | 0 |
| GREWAL HARPREET SINGH | Director | Sale | Apr 1, 2026 | 8,719 |
| KASSING DON W | Director | Stock Award(Grant) | Feb 13, 2025 | 9,909 |
| LEEDS JANET | Director | Stock Award(Grant) | Feb 12, 2026 | 6,639 |
| NARAYAN SHRUTHI | President | Stock Award(Grant) | Aug 16, 2026 | 33,880 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.91% | 4,297,555 | 1.37B | Jun 29, 2026 |
| HBK Investments L P | 4.67% | 1,838,508 | 586.81M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.34% | 1,709,877 | 545.75M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.23% | 1,667,276 | 532.15M | Jun 29, 2026 |
| State Street Corporation | 3.16% | 1,243,258 | 396.82M | Jun 29, 2026 |
| ExodusPoint Capital Management, LP | 2.77% | 1,090,430 | 348.04M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,403,042 | 447.82M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,186,100 | 378.57M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.17% | 856,690 | 273.43M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.26% | 494,387 | 157.80M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14% | 450,774 | 143.88M | Jun 29, 2026 |
| SmallCap World Fund Inc | 1.05% | 412,644 | 131.71M | Sep 29, 2026 |